The clinical development of obinutuzumab for the treatment of follicular lymphoma

Impressive progress has been made in recent decades for advanced-stage follicular lymphoma with the availability of anti-CD20 monoclonal antibodies, initially rituximab and more recently obinutuzumab. Obinutuzumab is a unique, third-generation, fully humanized glycoengineered IgG(1) type II anti-CD2...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Barbara, Ujjani, Chaitra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5391868/
https://www.ncbi.nlm.nih.gov/pubmed/28435325
http://dx.doi.org/10.2147/CMAR.S114526

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5391868/
https://www.ncbi.nlm.nih.gov/pubmed/28435325
http://dx.doi.org/10.2147/CMAR.S114526

Ejemplares similares